Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology
14.1.2025 10:00:00 CET | Business Wire | Press release
Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed roundSince the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough new multi-scale, multi-modal foundation model for biology in 2025The new model will allow the simulation of biology at unprecedented scale and dimension, creating biological innovation for medical, biotech, cosmetic industries, and beyond
Bioptimus, the pioneering AI foundation model company, announced today that it has reached a significant funding milestone of $76 million. This total includes a $41 million cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf. The funding will accelerate Bioptimus’s mission to build the world’s first universal AI foundation model for biology, aimed at revolutionizing research and innovation across the medical, biotech, cosmetic industries, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114054102/en/
The company has been building momentum this year, assembling a world-class team, securing access to unique data sources, and successfully releasing its first model, H-Optimus-0, the world’s largest foundation model for pathology. H-Optimus-0 has already outperformed all other pathology models in independent benchmarks, including assessments conducted by Harvard Medical School’s HEST program1 and the University of Leeds.2 These studies highlighted the model’s unparalleled ability to predict gene expression from morphology and to subtype ovarian cancer with exceptional accuracy.
Breaking Down Silos in Biology
Bioptimus is redefining how we approach biological research by addressing a longstanding issue: the siloed nature of biological understanding. Historically, research has focused on isolated biological components, such as DNA, proteins, cells or tissues. Even existing AI foundation models operate within these silos, limiting their potential impact. Bioptimus’s revolutionary approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology as it exists in reality.
Jean-Philippe Vert, co-founder and CEO of Bioptimus, stated: “What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity. By learning how biology works directly from raw data across scales, from molecules to whole organisms, our model will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes and response to treatment, and design therapies with unprecedented precision. Beyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine. Essentially, it’s like the GPT of biology—but instead of generating text, we’re simulating biology.”
The funding will enable Bioptimus to enhance its multi-modal AI platform, integrating even more diverse data sources and therapeutic areas, forge strategic partnerships with pharmaceutical and biotech companies and expand critical datasets to further refine and validate its models.
Jacky Abitbol, Partner at Cathay Innovation, said: "Bioptimus is at the forefront of transforming biological research, leveraging cutting-edge AI to break down silos and unlock the full complexity of biology. By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond. We are delighted to see that since our initial investment a year ago, Bioptimus has succeeded in structuring a world-class team, while achieving key milestones in its development, notably with the launch of its AI foundation model for pathology in July, the largest in the world."
By combining the power of AI with a truly integrated view of biology, Bioptimus will empower researchers and multiple industries to solve some of the most complex challenges in medicine, biotechnology, and beyond.
For more information, visit bioptimus.com.
About Cathay Innovation
Cathay Innovation is a multistage venture capital firm, affiliated to Cathay Capital, investing in founders building transformative businesses across Europe, North America, Asia, Latin America and Africa. Its platform connects founders with investors and its ecosystem of leading Fortune500 corporations to help startups scale and transform industries with consumer to enterprise and AI solutions in commerce, fintech, digital health and mobility / energy. Founded in Paris in 2015, Cathay Innovation now manages over €2.5B AUM with additional offices in Berlin, San Francisco, Shanghai and Singapore and has invested in over 100 startups including Chime, Pinduoduo (NASDAQ: PDD), Glovo, Wallbox (NYSE: WBX), Owkin, Getaround, Ledger, ZenBusiness, Alma, Descartes Underwriting and more.
To learn more, visit us at www.cathayinnovation.com or follow us on LinkedIn or Twitter @cathayinnov.
| ____________________________________ |
1 Mahmood Lab, 2024. HEST: Hierarchical Embedding of Spatial Transcriptomics. Available at: https://github.com/mahmoodlab/HEST |
2 Arxiv.org, 2024. A New Model for Data Processing in Neural Networks. Available at: https://arxiv.org/abs/2405.09990 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114054102/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Media Release: Financial Worries Rise and Match Health Concerns as Cost-of-Living Pressures Mount in 20266.7.2026 10:00:00 CEST | Press release
Globally, people are united in their top personal worries: Financial and health issues rank at the top in 2026, averaging 13 percentage points ahead of other concerns.Financial pressure is prominent across Europe, rising in France, Germany, and U.K., and emerging as a top concern in newly measured markets, Spain and Switzerland.Allianz published these results in “The Allianz 3am Report 2026,” which surveyed 10,000 people across 10 countries worldwide about what keeps them awake at night.Addressing financial concerns requires accessible, targeted financial and risk education. To support this, Allianz has launched the “Allianz School For Life” learning platform. Households around the world are feeling the strain of the rising cost of living, with financial pressure increasingly shaping everyday choices and long-term confidence. Finances and health are now tied as the top global worries, at 48% each, followed by concerns about the future at 35%, according to consumer surveys in 10 countri
HAZAMA ANDO Becomes an Official Partner in Helical Fusion’s Commercial Fusion Initiative and Signs MoU Toward Construction of the Fusion Pilot Plant6.7.2026 08:40:00 CEST | Press release
A long-established Japanese general contractor will contribute construction expertise to advance Fusion Pilot Plant development toward commercially viable fusion power. Helical Fusion Co., Ltd. (“Helical Fusion”), a Japan-based fusion energy startup developing fusion power plants, and HAZAMA ANDO CORPORATION (“HAZAMA ANDO”), a long-established Japanese general contractor, today announced that HAZAMA ANDO has become an Official Partner in the Helix Program, Helical Fusion’s commercial fusion initiative. The two companies have also signed a memorandum of understanding (“MoU”) to collaborate toward the construction of Helix KANATA, Helical Fusion’s Fusion Pilot Plant targeted for the 2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706176052/en/ (L-R) Kazuhiko Kuniya (Representative Director and President, HAZAMA ANDO CORPORATION) and Takaya Taguchi (Co-Founder and CEO, Helical Fusion Co., Ltd.) at a press conference in
Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis6.7.2026 07:15:00 CEST | Press release
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exitThe proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor typesMyricx Bio's first-in-class NMTi payload platform is designed to improve the therapeutic index of ADCs, offering the potential for more effective and better-tolerated treatment options for cancer patientsThe transaction valued at up to $1.5 billion including $1.1 billion cash upfront Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. This marks Sofinnova Partners' seventh exit in three years. Myricx Bio is a UK-headquartered transatlantic biotech company focused on the discove
Global New Material International Wins Technology Innovation Best Practice Award at Sino-European ESG Conference6.7.2026 05:59:00 CEST | Press release
Global New Material International Holdings Ltd. has received the Technology Innovation Best Practice Award at the Third Sino-European Corporate ESG Best Practice Conference recently in Mainz, Germany, in recognition of its efforts to advance sustainable development through material innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260705533555/en/ Thorsten Giehler (L), Director of the Economic, Social Development and Employment Division of The German Society for International Cooperation (GIZ), delivered the award to Zhou Fangchao, Executive Director and Vice President of Global New Material International. The annual conference, initiated by the Chinese Consulate General in Frankfurt and jointly organized with Chinese and European partners, recognizes corporate best practices in environmental, social and governance (ESG) performance. This year's event brought together government officials, business leaders and exper
Access Advance Welcomes Samsung and Sharp to the VVC Advance Patent Pool6.7.2026 02:00:00 CEST | Press release
Access Advance LLC today announced significant additions to the VVC Advance Patent Pool, including Samsung Electronics and Sharp Corporation joining as both Licensors and Licensees. The additions strengthen Access Advance's position in VVC licensing, bringing two of the world's largest video codec patent holders into the program on both sides of the license. "The growth we are seeing in VVC Advance reflects the broad range of industries and companies that are moving toward VVC as the next standard for video delivery," said Peter Moller, CEO of Access Advance. "Samsung and Sharp joining as both Licensors and Licensees is significant, but so is the participation of leading smartphone brands and the range of consumer electronics and technology companies now executing licenses. We are building a program that reflects where the video market is actually heading." The following companies have joined the VVC Advance Patent Pool as Licensees since the beginning of 2026: American Future Technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom